Basilea Pharmaceutica AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 2000-01-01
- Employees
- 147
- Market Cap
- $676.7M
- Website
- http://www.basilea.com
Safety, Pharmacokinetics, Bioavailability, Food Effect, Drug-Drug Interaction Study of APX001 Administered Orally
- Conditions
- Interventions
- Drug: APX001 single oral dose 2Drug: APX001 single oral dose 3Drug: APX001 multiple oral doses 2Drug: APX001 single IV doseDrug: APX001 single oral dose fastedDrug: APX001 single oral dose fedDrug: APX001 multiple oral doses 1Drug: APX001 single oral dose 1Drug: Matching placebo controlDrug: APX001 multiple oral doses 3Drug: Cytochrome P450 substrates
- First Posted Date
- 2016-11-08
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Basilea Pharmaceutica
- Target Recruit Count
- 46
- Registration Number
- NCT02957929
- Locations
- 🇳🇱
PRA Health Sciences (PRA) - Early Development Services (EDS), Groningen, Netherlands
🇳🇱PRA Health Sciences, Groningen, Netherlands
Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2016-11-06
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Basilea Pharmaceutica
- Target Recruit Count
- 200
- Registration Number
- NCT02956499
- Locations
- 🇳🇱
PRA Health Sciences, Groningen, Netherlands
Phase 1/2a Study of BAL101553 as 48-hour Infusions in Patients With Advanced Solid Tumors or Recurrent Glioblastoma
- First Posted Date
- 2016-09-09
- Last Posted Date
- 2023-05-10
- Lead Sponsor
- Basilea Pharmaceutica
- Target Recruit Count
- 43
- Registration Number
- NCT02895360
- Locations
- 🇨🇭
UniversitaetsSpital Zürich, Zürich, Switzerland
🇨🇭Oncology Institute of Southern Switzerland; Ospedale Regionale San Giovanni Bellinzona e Valli, Bellinzona, Switzerland
🇨🇭Cantonal Hospital of Grisons, Department of Oncology/ Haematology, Chur, Switzerland
Pharmacokinetics and Safety of Ceftobiprole in Neonates and Infants up to 3 Months Treated With Systemic Antibiotics
- First Posted Date
- 2015-08-19
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- Basilea Pharmaceutica
- Target Recruit Count
- 15
- Registration Number
- NCT02527681
- Locations
- 🇱🇹
Vilnius University Children's Hospital, Vilnius, Lithuania
🇱🇻Children Clinical University Hospital, Riga, Latvia
🇺🇸Loma Linda University Medical Center, Loma Linda, California, United States
Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade Glioma
- Conditions
- Interventions
- First Posted Date
- 2015-07-07
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Basilea Pharmaceutica
- Target Recruit Count
- 72
- Registration Number
- NCT02490800
- Locations
- 🇧🇪
UZ Leuven, Leuven, Belgium
🇩🇪Klinikum der Goethe-Universität Frankfurt, Frankfurt, Germany
🇩🇪Universitätsklinikum Regensburg, Regensburg, Germany
Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations
- First Posted Date
- 2012-12-19
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- Basilea Pharmaceutica
- Target Recruit Count
- 119
- Registration Number
- NCT01752920
- Locations
- 🇮🇹
Istituto Clinico Humanitas, Milan, Italy
🇮🇹Instituto Oncologico Veneto, IRCCS, Padova, Italy
🇮🇹Azienda Ospedaliero-Universitaria Pisana - U.O. Oncologia Medica 2 Univ., Pisa, Italy
An Open-Label Study of Intravenous BAL101553 in Adult Patients With Solid Tumors
- First Posted Date
- 2011-07-20
- Last Posted Date
- 2023-05-10
- Lead Sponsor
- Basilea Pharmaceutica
- Target Recruit Count
- 73
- Registration Number
- NCT01397929
- Locations
- 🇬🇧
Royal Marsden Hospital, Sutton, Surrey, United Kingdom
🇬🇧Sir Bobby Robson Cancer Trials Research Centre; Northern Centre for Cancer Care, Newcastle upon Tyne, United Kingdom
🇬🇧University College London NHS Foundation Trust, London, United Kingdom
Pharmacokinetic Study,Ceftobiprole,Healthy Volunteers,Healthy Patients With End Stage Renal Disease
- Conditions
- Interventions
- First Posted Date
- 2009-12-11
- Last Posted Date
- 2012-08-28
- Lead Sponsor
- Basilea Pharmaceutica
- Target Recruit Count
- 12
- Registration Number
- NCT01030731
Evaluation of Penetration of Ceftobiprole Into Soft Tissue Determined by Microdialysis in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2009-12-04
- Last Posted Date
- 2012-07-30
- Lead Sponsor
- Basilea Pharmaceutica
- Target Recruit Count
- 15
- Registration Number
- NCT01026740
A Single-Dose Pharmacokinetics and Safety Study of Ceftobiprole in Pediatric Patients =3 Months to <18 Years of Age
- Conditions
- Interventions
- First Posted Date
- 2009-12-04
- Last Posted Date
- 2012-07-27
- Lead Sponsor
- Basilea Pharmaceutica
- Target Recruit Count
- 64
- Registration Number
- NCT01026636